Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck;Valor diagnóstico de los marcadores E-cadherina, MMP-9, MMP-13 activada y de los anticuerpos anti-p53 en el carcinoma escamoso de cabeza y cuello

Medicina Clinica

Volumn 129, Issue 20, 2007, Pages 761-765

  Al Kassam, Daniel ^a,d   Marcos, César Álvarez ^a   Blanco, Ignacio ^a   De Los Toyos, Juan Ramón ^b   Llorente, José Luis ^c  

^a Servicio de Medicina Interna   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL VALLE DEL NALÓN   (Spain)

Author keywords

Head and neck cancer; Metastasis; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; COLLAGENASE 3; GELATINASE A; GELATINASE B; PROTEIN ANTIBODY; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MALE; SQUAMOUS CELL CARCINOMA;

EID: 37749054894     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13113764     Document Type: Article

References (37)

1. Morales M, Llopis A, Moreno E, Martínez M, Vitoria I, Givert V. Hábitos tóxicos en relación con el cáncer de laringe. Acta Otorrinolaringol Esp. 1997;44:45-50.
2. Eibling D, Johnson J, Wagner R. Radioimmunoassay for SCC antigen in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope. 1989;99:117-24.
3. Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M, et al. Cyfra 21.1: a new potential tumor marker for squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1995;121:177-81.
4. Bracke M, Van Roy F, Mareel M. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol. 1996;213:123-61.
5. Mbalaviele G, Dustan CR, Susaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastasis in an experimental metastasis model. Cancer Res. 1996;56:4063-70.
6. Schippper JH, Frixen UH, Behrens J, Unger A. E-cadherin expresion in squamous cell carcinomas of head and neck: inverse correlation with tumor diferentiation and lymph node metastasis. Cancer Res. 1991;51:6328-37.
7. Bracke M, Van Roy F, Mareel M. The E-cadherin/catenin complex in invasion and metastasis. Curr Top Microbiol Immunol. 1996;213:123-61.
8. Wheelock MJ, Buck CA, Bechtol KB, Damsky CH. Soluble 80-kd fragment of cell-CAM 120/80 disrupts cell-cell adhesion. J Cell Biochem. 1987;34:187-202.
9. Katayama M, Hirai S, Kamihagi K, Nakagawa K, Yasumoto M, Kato I. Soluble E-cadherin fragments increased in circulation of cancer patients. Br J Cancer. 1994;69:580-5.
10. Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CH, et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer. 1996;74:579-84.
11. Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J, et al. Assay of E-cadherin by ELISA in human breast cancers. Eur J Cancer. 1997;33:404-8.
12. Powel W, Matrisian LM. Complex roles of matrix metalloproteinases in tumor progresion. Curr Top Microbiol Inmunol. 1996;213:1-21.
13. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinase in metastasis. J Natl Cancer Inst. 1997;89:1262-70.
14. Freije JP, Díez-Itza I, Balbín M, Sánchez LM, Blasco R, Tolivia J, et al. Molecular cloning and expression of collagenase-3, a novel matrix matalloproteinase produced by breast carcinomas. J Biol Chem. 1994;269:16766-73.
15. Puente XS, Pendás AM, Llano E, Velasco G, López-Otín C. Molecular cloning of a novel membrane-type matrix metalloproteinase from human breast carcinoma. Cancer Res. 1996; 56:944-9.
16. Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer. 2002;95:1902-10.
17. Cazorla M, Hernández L, Nadal A, Balbín M, López JM, Vizoso F, et al. Collagenase-3 expresion is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol. 1998;186:144-50.
18. Angelopoulou K, Diamandis EP, Sutheland DJ, Kellen JA, Buting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994;58:480-7.
19. Bourhis J, Lubin R, Roche B, Koscidny S. Analysis of p53 serum antibodies in patients with squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1228-33.
20. Lavieille J, Lubin R, Soussi T, Reyt E, Brambilla C. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res. 1996;16:2385-8.
21. Altman D, Bossuyt P. Estudios de precisión diagnóstica (STARD) y pronóstica (REMARK). Med Clin (Barc). 2005;125 suppl 1:49-55.
22. Kuefer R, Hofer MD, Zorn CS, Engel O, Volkmer BG, Juárez-Brito MA, et al. Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer. Br J Cancer. 2005;92:2018-23.
23. Rodrigo JP, Domínguez F, Álvarez C, Manrique C, Herrero A, Suárez C. Expression of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer. 2002;38:1059-64.
24. Kuropkat C, Plehn S, Herz U, Dunne AA, Renz H, Werner JA. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res. 2002;22:2221-7.
25. Riedel F, Gotte K, Schwalb J, Hormann K. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Res. 2000;20:3045-9.
26. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S, et al. Metalloproteinases and their inhibitors: Influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck. 2006;28:31-9.
27. Xu YP, Zhao XQ, Sommer K, Moubayed P. Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J Zhejiang Univ Sci. 2003;4:491-501.
28. Kuropkat C, Duenne AA, Herz U, Renz H, Werner JA. Significant correlation of matrix metalloproteinase and macrophage colony-stimulating factor serum concentrations in patients with head and neck cancer. Neoplasma. 2004;51:375-8.
29. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S, et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res. 2005;33:44-50.
30. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158-66.
31. Hofele C, Schwager-Schmitt M, Volkmann M. Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma-five years survival rate Laryngorhinootologie. 2002;81:342-5.
32. Chow V, Yuen AP, Lam KY, Ho WK, Wei WI. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck. 2001;23:286-91.
33. Bourhis J, Lubin R, Roche B, Koscidny S. Analysis of p53 serum antibodies in patients with squamous cell carcinoma. J Natl Cancer Inst. 1996;88:1228-33.
34. Lavieille J, Lubin R, Soussi T, Reyt E, Brambilla C. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res. 1996;16:2385-8.
35. Ralhan R, Nath N, Agarwal S, Mathur M, Wasylyk B, Shukla NK. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res. 1998;4:2147-52.
36. Wollenberg B, Jan NV, Pitzke P, Reiter W, Stieber P. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. Anticancer Res. 1997;17:413-8.
37. Maass JD, Gottschlich S, Goeroegh T, Lippert BM, Werner JA. Head and neck cancer and p53-immunogenicity. Anticancer Res. 1997;17:2873-4.